Fly­ing so­lo for a change, Sanofi says isat­ux­imab scored an im­por­tant suc­cess in first PhI­II myelo­ma study

Maybe Sanofi can de­vel­op a ma­jor new on­col­o­gy drug on its own.

Ear­ly Tues­day the phar­ma gi­ant an­nounced the suc­cess­ful — topline — Phase III out­come for isat­ux­imab, its an­ti-CD38 treat­ment for mul­ti­ple myelo­ma. Re­searchers said the drug hit the end­point on pro­gres­sion-free sur­vival among pa­tients who had been treat­ed with at least two ear­li­er ther­a­pies.

There’s no da­ta yet, but it will be close­ly watched when Sanofi does post the re­sults as it hus­tles a new drug ap­pli­ca­tion to reg­u­la­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.